NCT02304497

Brief Summary

Diabetic patients may show different release of growth factors when microvascular complications such as; retinopathy or periodontitis are seen. Diabetes have an adverse effect on periodontal health and periodontal infection have an adverse effect on glycemic control and incidence of diabetes complications. Therefore, the investigators hypothesize that growth factors levels releasing from platelet rich fibrin (PRF) in diabetes mellitus (DM) may be decrease because of periodontitis is considered to be the sixth microvascular complication of diabetes or diabetes may have inductive effect on PRF growth factors levels in periodontal disease. Determination of PRF growth factors levels may be beneficial to treatment of diabetic patient with periodontal disease by using PRF.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2013

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2014

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

November 21, 2014

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 2, 2014

Completed
Last Updated

December 2, 2014

Status Verified

December 1, 2014

Enrollment Period

1.3 years

First QC Date

November 21, 2014

Last Update Submit

December 1, 2014

Conditions

Keywords

Diabetes mellitusPlatelet rich fibringrowth factor

Outcome Measures

Primary Outcomes (6)

  • Platelet Rich Fibrin (PRF) levels of vascular endothelial growth factor (VEGF)

    Baseline

  • PRF levels of platelet derived growth factor- AB (PDGF-AB)

    Baseline

  • PRF levels of basic- fibroblast growth factor (b-FGF)

    Baseline

  • PRF levels of transforming growth factor- beta 1 (TGF-β1)

    Baseline

  • PRF levels of transforming growth factor- beta 2 (TGF-β2)

    Baseline

  • PRF levels of insulin like growth factor -1 (IGF-1)

    Baseline

Study Arms (4)

DM-CTRL

Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained

Other: Platelet Rich Fibrin

DM-CP

Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained

Other: Platelet Rich Fibrin

CP

Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained

Other: Platelet Rich Fibrin

CTRL

Periodontally and systemically healthy subject Platelet Rich Fibrin obtained

Other: Platelet Rich Fibrin

Interventions

Procedure: Platelet Rich Fibrin obtained

CPCTRLDM-CPDM-CTRL

Eligibility Criteria

Age40 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The patients participating the study were recruited from indivuduals referred to Department of Periodontology, Faculty of Dentistry, University of Bülent Ecevit University for either dental treatment or dental check-ups.

You may qualify if:

  • CP patients required a diagnosis of moderate to advanced CP and showing radiographic evidence of bone loss and, defined as clinical attachment loss with a minimum of 6 teeth having periodontal pocket greater than 4 mm, a minimum of 20 natural teeth,
  • No periodontal treatment in the prior 6 months.
  • T2DM patients who had HbA1c levels between 6%-8 %
  • Periodontally healthy subjects (periodontal pocket depth \< 4 mm)

You may not qualify if:

  • If they had any known systemic diseases other than type 2 diabetes mellitus
  • Patient had been under medicine treatment for at least 6 months except patients with diabetes who were treated with stable doses of hypoglycemic agents
  • Patients with major complications of DM (i.e., cardiovascular and peripheral vascular diseases
  • Insufficient platelet count (\<200,000/mm3); 2) pregnancy/lactation )
  • Tobacco use
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes MellitusChronic Periodontitis

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesPeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Şeyma Bozkurt Doğan, DDS

    Bülent Ecevit University Faculty of Dentistry

    STUDY CHAIR
  • Umut Ballı, DDS

    Bülent Ecevit University Faculty of Dentistry

    PRINCIPAL INVESTIGATOR
  • Figen Öngöz Dede, DDS

    Bülent Ecevit University Faculty of Dentistry

    STUDY DIRECTOR
  • Mustafa Cenk Durmuşlar, DDS

    Bülent Ecevit University Faculty of Dentistry

    PRINCIPAL INVESTIGATOR
  • Murat Can, Assoc. Professor

    Bülent Ecevit University Faculty of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD, DDS

Study Record Dates

First Submitted

November 21, 2014

First Posted

December 2, 2014

Study Start

March 1, 2013

Primary Completion

July 1, 2014

Study Completion

November 1, 2014

Last Updated

December 2, 2014

Record last verified: 2014-12